Search

Displaying results 1221 - 1230 of 4575 in total
  1. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects … The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the

  2. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States

  3. Drug

    Cefoxitin

    go.drugbank.com/drugs/DB01331
    ApprovedInvestigational

    It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.

  4. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  5. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

  6. Drug

    Fludeoxyglucose (18F)

    go.drugbank.com/drugs/DB09502
    ApprovedInvestigational

    It is administered by intravenous injection.

  7. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.

  8. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

  9. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

  10. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma